AvalehtWXXWY • OTCMKTS
add
Wuxi Biologics Cayman ADR
Viimane sulgemishind
2,77 $
Tänane vahemik
2,72 $ - 2,76 $
Aasta vahemik
2,69 $ - 13,25 $
Turuväärtus
48,43 mld HKD
Keskmine maht
85,57 tuh
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (CNY) | dets 2023info | Y/Y muutus |
|---|---|---|
Käive | 4,27 mld | 5,95% |
Põhitegevusega seonduv kulu | 818,44 mln | 13,31% |
Puhastulu | 566,53 mln | −39,90% |
Puhaskasumimarginaal | 13,26 | −43,28% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 1,06 mld | −1,78% |
Tõhus maksumäär | 25,05% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (CNY) | dets 2023info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 11,24 mld | 29,02% |
Kogu vara | 56,58 mld | 14,15% |
Kõik kohustused | 12,56 mld | −5,94% |
Kogu omakapital | 44,02 mld | — |
Emiteeritud aktsiate arv | 4,22 mld | — |
Hinna ja väärtuse suhe P/B | 0,29 | — |
Varade tasuvus | 3,60% | — |
Kapitali tasuvus | 4,19% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (CNY) | dets 2023info | Y/Y muutus |
|---|---|---|
Puhastulu | 566,53 mln | −39,90% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tegevjuht
Asutatud
2010
Veebisait
Töötajate arv
12 740
